These days, Biotherapeutics are the rapidly growing group of pharmaceuticals, actually for a treatment option, a variety of chronic and sometimes life-threatening conditions. Those represent a dissimilar group of biological preparations that widely encompasses nucleic acids, proteins, whole cells, viral particles, and vaccines.
In recent years, great progress has been made regarding the development of safe and effective Biotherapeutics, and in the adoption of cost-effective, more efficient, and modernized manufacturing processes. This trend looks forward to accelerating in the forthcoming years, as emerging fields related to advanced therapies or personalized medicine mature.
Advances in Drug Discovery and Development
Any Procedure which is applied to drug discovery and development by the medical community and pharmaceutical industry has a direct change in the further availability of better, innovative, and therapeutic treatment for patients with cancer. Drug discovery is defined as a complicated learning technique whereby research efforts are directed towards discover and assimilating new innovative thoughts to produce a drug to provide a benefit to a patient population.
Subsequently, a highly useful technology or approach to drug discovery should give both effective thoughts and the applications of newly discovered observations that can be utilized for therapeutic benefit.
Title : Nanomaterial-mediated systemically administered m-RNA-based gene therapy directed exclusively to cancer, present successes and future prospects
A C Matin, Stanford University, United States
Title : Personalized and precision medicine (PPM) as a unique healthcare model to be set up via biodesign, bio- and chemical engineering, translational applications, and upgraded business modeling to secure the human healthcare and biosafety
Sergey Suchkov, The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation
Title : Clinical pharmacology of aprocitentan (an endothelin receptor antagonist) – The most recent quality progress in treatment of resistant hypertension
Miroslav Radenkovic, University of Belgrade, Serbia
Title : Clinical decision making in advanced and metastatic breast cancer cases between PARP inhibitors and CDK4/6 inhibitors
Priya Hays, Hays Documentation Specialists, LLC, United States
Title : Emerging formulation and delivery applications of vitamin E TPGS
Andreas M Papas, Antares Health Products, United States
Title : Novel nano drug platform for pharmacologically inducing therapeutic hypothermia (TH) after traumatic brain injury (TBI)
Jorge David Tovar Castro, University of Miami Miller School of Medicine, United States
Title : Global drug development - Trends, challenges and opportunities
Gurpreet Singh, IQVIA, United Kingdom
Title : Drug design for the development of long-acting injectables
Thomas Ullrich, Novartis Biomedical Research, Switzerland
Title : Synthesis and properties of new unique heterocyclic systems: Pyrido[3'',2'':4',5']furo(thieno)[3',2':4,5]pyrimido[2,1-f][1,2,4]triazines
Anush, National Academy of Sciences of the Republic of Armenia, Armenia
Title : Development and evaluation of prolonged-release dutasteride transdermal delivery system
Shereen M. Assaf, Jordan University of Science and Technology, Jordan